Vedolizumab as first line biologic therapy in elderly patients with contraindications against anti-TNF therapy - A real-world nationwide cohort of patients with inflammatory bowel diseases

M Attauabi; C Hoglund; J Fassov; K B Pedersen; H Bansholm Hansen; S Wildt; M Dam Jensen; A Neumann; C Lind; H Albaek Jacobsen; A M Popa; J Kjeldsen; N Pedersen; A Molazahi; K Haderselv; C Aalykke; T Knudsen; W Cebula; P Munkholm; F Bendtsen; J B Seidelin; B Johan

doi:10.1093/ecco-jcc/jjab076.471

Vedolizumab as first line biologic therapy in elderly patients with contraindications against anti-TNF therapy - A real-world nationwide cohort of patients with inflammatory bowel diseases

M Attauabi, C Hoglund, J Fassov, K B Pedersen, H Bansholm Hansen, S Wildt, M Dam Jensen, A Neumann, C Lind, H Albaek Jacobsen, A M Popa, J Kjeldsen, N Pedersen, A Molazahi, K Haderselv, C Aalykke, T Knudsen, W Cebula, P Munkholm, F BendtsenJ B Seidelin, B Johan

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

Originalsprog	Engelsk
Tidsskrift	Journal of Crohn's & colitis
Vol/bind	15
Udgave nummer	Suppl. 1
Sider (fra-til)	S369-S370
Antal sider	2
ISSN	1873-9946
DOI	https://doi.org/10.1093/ecco-jcc/jjab076.471
Status	Udgivet - maj 2021
Begivenhed	16th Congress of ECCO Virtual - Virtual Congress Varighed: 2 jul. 2021 → 10 jul. 2021 https://www.ecco-ibd.eu/ecco21.html

Konference

Konference	16th Congress of ECCO Virtual
Lokation	Virtual Congress
Periode	02/07/2021 → 10/07/2021
Internetadresse	https://www.ecco-ibd.eu/ecco21.html

Bibliografisk note

Abstrakt No. P347

Adgang til dokumentet

10.1093/ecco-jcc/jjab076.471

AUB Link

Søg efter materialet i Aalborg Universitetsbiblioteks søgemaskine

Citationsformater

Attauabi, M., Hoglund, C., Fassov, J., Pedersen, K. B., Hansen, H. B., Wildt, S., Jensen, M. D., Neumann, A., Lind, C., Jacobsen, H. A., Popa, A. M., Kjeldsen, J., Pedersen, N., Molazahi, A., Haderselv, K., Aalykke, C., Knudsen, T., Cebula, W., Munkholm, P., ... Johan, B. (2021). Vedolizumab as first line biologic therapy in elderly patients with contraindications against anti-TNF therapy - A real-world nationwide cohort of patients with inflammatory bowel diseases. Journal of Crohn's & colitis, 15(Suppl. 1), S369-S370. https://doi.org/10.1093/ecco-jcc/jjab076.471

@article{0a29c24ed20a443bb3b492697ba59cb2,

title = "Vedolizumab as first line biologic therapy in elderly patients with contraindications against anti-TNF therapy - A real-world nationwide cohort of patients with inflammatory bowel diseases",

author = "M Attauabi and C Hoglund and J Fassov and Pedersen, {K B} and Hansen, {H Bansholm} and S Wildt and Jensen, {M Dam} and A Neumann and C Lind and Jacobsen, {H Albaek} and Popa, {A M} and J Kjeldsen and N Pedersen and A Molazahi and K Haderselv and C Aalykke and T Knudsen and W Cebula and P Munkholm and F Bendtsen and Seidelin, {J B} and B Johan",

note = "Abstract No. P347; 16th Congress of ECCO Virtual ; Conference date: 02-07-2021 Through 10-07-2021",

year = "2021",

month = may,

doi = "10.1093/ecco-jcc/jjab076.471",

language = "English",

volume = "15",

pages = "S369--S370",

journal = "Journal of Crohn's & colitis",

issn = "1873-9946",

publisher = "Oxford University Press",

number = "Suppl. 1",

url = "https://www.ecco-ibd.eu/ecco21.html",

}

Attauabi, M, Hoglund, C, Fassov, J, Pedersen, KB, Hansen, HB, Wildt, S, Jensen, MD, Neumann, A, Lind, C, Jacobsen, HA, Popa, AM, Kjeldsen, J, Pedersen, N, Molazahi, A, Haderselv, K, Aalykke, C, Knudsen, T, Cebula, W, Munkholm, P, Bendtsen, F, Seidelin, JB & Johan, B 2021, 'Vedolizumab as first line biologic therapy in elderly patients with contraindications against anti-TNF therapy - A real-world nationwide cohort of patients with inflammatory bowel diseases', Journal of Crohn's & colitis, bind 15, nr. Suppl. 1, s. S369-S370. https://doi.org/10.1093/ecco-jcc/jjab076.471

Vedolizumab as first line biologic therapy in elderly patients with contraindications against anti-TNF therapy - A real-world nationwide cohort of patients with inflammatory bowel diseases. / Attauabi, M; Hoglund, C; Fassov, J et al.
I: Journal of Crohn's & colitis, Bind 15, Nr. Suppl. 1, 05.2021, s. S369-S370.

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

TY - ABST

T1 - Vedolizumab as first line biologic therapy in elderly patients with contraindications against anti-TNF therapy - A real-world nationwide cohort of patients with inflammatory bowel diseases

AU - Attauabi, M

AU - Hoglund, C

AU - Fassov, J

AU - Pedersen, K B

AU - Hansen, H Bansholm

AU - Wildt, S

AU - Jensen, M Dam

AU - Neumann, A

AU - Lind, C

AU - Jacobsen, H Albaek

AU - Popa, A M

AU - Kjeldsen, J

AU - Pedersen, N

AU - Molazahi, A

AU - Haderselv, K

AU - Aalykke, C

AU - Knudsen, T

AU - Cebula, W

AU - Munkholm, P

AU - Bendtsen, F

AU - Seidelin, J B

AU - Johan, B

N1 - Abstract No. P347

PY - 2021/5

Y1 - 2021/5

U2 - 10.1093/ecco-jcc/jjab076.471

DO - 10.1093/ecco-jcc/jjab076.471

M3 - Conference abstract in journal

SN - 1873-9946

VL - 15

SP - S369-S370

JO - Journal of Crohn's & colitis

JF - Journal of Crohn's & colitis

IS - Suppl. 1

T2 - 16th Congress of ECCO Virtual

Y2 - 2 July 2021 through 10 July 2021

ER -